Superpower peptides available for pre-order. Get first access.

Peptide science

FDA-approved

What is orforglipron (Foundayo)?

Orforglipron is Foundayo, an FDA-approved oral non-peptide GLP-1 receptor agonist for weight management. Learn the mechanism, trial data, and status.

EvidenceFDA approved
ClassOral GLP-1 receptor agonist (non-peptide)

Quick answer

Orforglipron, sold as Foundayo, is a once-daily oral small-molecule GLP-1 receptor agonist from Eli Lilly, approved by the FDA on April 1, 20261, for chronic weight management. Unlike most peptide GLP-1 drugs, it needs no injection. In the ATTAIN-1 Phase 3 trial, 36 mg produced 11.2% mean weight loss at 72 weeks2 vs 2.1% with placebo in 3,127 adults with obesity.

Published
April 18, 2026
Last updated
November 12, 2026

At a glance

ClassOral GLP-1 receptor agonist (non-peptide)
In the USFDA-approved as Foundayo (April 1, 2026) for chronic weight management
EvidenceFDA approved

At a glance

ItemDetail
StatusFDA-approved prescription drug as of November 2026, approved as Foundayo on April 1, 20261
Brand nameFoundayo
MakerEli Lilly and Company
Molecule typeNon-peptide small molecule3 that activates the GLP-1 receptor
FormOnce-daily oral tablet4, taken with or without food
Approved useChronic weight management in adults with obesity, or overweight plus at least 1 weight-related condition
Prescribing informationCurrent Foundayo label4
Superpower offerSuperpower does not offer orforglipron

What is orforglipron?

Orforglipron, sold as Foundayo, is a once-daily oral small-molecule GLP-1 receptor agonist made by Eli Lilly. The FDA approved orforglipron on April 1, 20261, for chronic weight management in adults with obesity, or overweight plus a weight-related condition.

Injectable GLP-1 drugs are peptides, short chains of amino acids. Orforglipron is a synthetic nonpeptide agonist3, developed under the code name LY35029705. That non-peptide structure changes how orforglipron reaches the bloodstream.

How oral orforglipron works

Orforglipron activates the human GLP-1 receptor4, the same target as injectable GLP-1 receptor agonists. As a small molecule, orforglipron works from a tablet with no injection, absorption enhancer, or fasting.

That receptor normally answers to GLP-1, a gut hormone that boosts insulin after meals, slows stomach emptying, and reduces food intake6.

Orforglipron binds the GLP-1 receptor selectively3. Orforglipron's elimination half-life is about 29 to 49 hours4, long enough for once-daily dosing5.

Oral semaglutide is a peptide, so its tablet relies on an absorption enhancer7 and is absorbed poorly unless taken fasted8.

In a US study of 125,474 adults with overweight or obesity starting GLP-1 drugs, 64.8% of those without diabetes stopped9 within a year. Orforglipron's own trials measured its effects on weight and blood sugar.

Orforglipron's Phase 2 and Phase 3 trial results

In Phase 3, orforglipron 36 mg lowered body weight 11.2% at 72 weeks2, vs 2.1% with placebo, in ATTAIN-1's 3,127 adults with obesity. In ATTAIN-2, 1,613 adults with obesity or overweight and type 2 diabetes on 36 mg lost 9.6% at 72 weeks10, vs 2.5%. In ACHIEVE-1, 559 adults with early type 2 diabetes saw HbA1c fall 1.48 percentage points11 (a three-month blood sugar average) on 36 mg at 40 weeks, vs 0.41.

Daily doses tested, with ATTAIN figures on the treatment-regimen estimand (every randomized participant counted, whether or not they stayed on the drug):

TrialPhasePopulationParticipantsWeeksDaily doses tested and mean result vs placeboStopped for adverse events
Phase 2 obesity2Adults with obesity, or overweight plus a comorbidity, no diabetes2723612 to 45 mg: weight −9.4% to −14.7%12 vs −2.3%10% to 17% stopped for digestive side effects
Phase 2 type 2 diabetes2Adults with type 2 diabetes on diet and exercise, with or without metformin383263 to 45 mg, largest dose-arm mean: HbA1c −2.1 points13 vs −0.43 with placebo and −1.1 with dulaglutide 1.5 mg weekly (same trial); weight −10.1 kg vs −2.2 kg and −3.9 kgNot reported
ACHIEVE-13Adults with early type 2 diabetes on diet and exercise only559403, 12, and 36 mg: HbA1c −1.24, −1.47, and −1.48 points11 vs −0.414.4% to 7.8% vs 1.4%
ATTAIN-13Adults with obesity, no diabetes3,127726, 12, and 36 mg: weight −7.5%, −8.4%, and −11.2%2 vs −2.1%5.3% to 10.3% vs 2.7%
ATTAIN-23Adults with obesity or overweight and type 2 diabetes1,613726, 12, and 36 mg: weight −5.1%, −7%, and −9.6%10 vs −2.5%6.1% to 9.9% vs 4.1%

Individual results varied widely. At 36 mg in ATTAIN-1, 54.6% lost at least 10% of body weight2, 36% at least 15%, and 18.4% at least 20%. Placebo shares were 12.9%, 5.9%, and 2.8%2.

Pooled across four placebo-controlled trials, orforglipron lowered weight 6.08% more than placebo14.

In the Phase 3b ATTAIN-MAINTAIN trial, adults whose weight had plateaued on tirzepatide or semaglutide switched to orforglipron or placebo for 52 weeks. Those on orforglipron kept 74.7% and 79.3% of prior weight loss15, respectively, vs 49.2% and 37.6% with placebo15.

ATTAIN-1 also saw improvements in waist size2, blood pressure, triglycerides, and non-HDL cholesterol, all heart and metabolic risk markers.

Orforglipron's cardiometabolic effects

Orforglipron was associated with lower blood pressure, LDL cholesterol, triglycerides, and hs-CRP16, an inflammation marker, vs placebo in an exploratory analysis of two Phase 2 trials.

ACHIEVE-4 followed 2,749 adults with type 2 diabetes17 and heart or kidney disease for a median two years. Major cardiovascular events occurred in 4.2%17 on orforglipron vs 5% on insulin glargine. The result shows safety against insulin rather than a proven drop in heart events.

Comparisons with other GLP-1 drugs rest mainly on weight loss.

Orforglipron vs other GLP-1 drugs

Orforglipron's 11.2% weight loss at 36 mg2 in ATTAIN-1 is numerically lower than the 14.9% seen with weekly semaglutide 2.4 mg18 in STEP 1. STEP 1 enrolled 1,961 adults with overweight or obesity18. Cross-trial comparisons like this are unreliable, since the trials differ in length, design, and populations.

ACHIEVE-3 did compare orforglipron directly with oral semaglutide in 1,698 adults with type 2 diabetes on metformin. After 52 weeks, orforglipron 12 and 36 mg lowered HbA1c 1.71 and 1.91 points19, vs 1.23 and 1.47 points19 with oral semaglutide 7 and 14 mg.

Tirzepatide activates both the GIP and GLP-1 receptors, while orforglipron activates only the GLP-1 receptor. No head-to-head trial has compared them20.

Danuglipron, another oral small-molecule GLP-1 agonist21, was taken twice daily in a 628-adult Phase 2b obesity trial22. About 38% stopped for adverse events22 over 26 to 32 weeks. Tolerability matters just as much for orforglipron.

Orforglipron side effects in clinical trials

Orforglipron's most common side effects in clinical trials are digestive, mostly mild to moderate2, and most frequent while the dose is being increased10. Reactions reported in at least 5% of people4 taking Foundayo include:

  • Nausea and vomiting
  • Diarrhea and constipation
  • Indigestion, reflux, belching, gas, and bloating
  • Abdominal pain
  • Headache, fatigue, and hair loss

ACHIEVE-1 recorded no severe hypoglycemia11, a dangerous blood sugar drop, in adults with early type 2 diabetes taking no other diabetes drug. Foundayo's label adds formal warnings.

Orforglipron (Foundayo) FDA approval and label status

As of November 2026, Foundayo is an FDA-approved prescription tablet for long-term weight reduction4 in adults with obesity, or overweight plus a weight-related condition. Foundayo is approved alongside a reduced-calorie diet and more physical activity.

Foundayo carries a boxed warning for thyroid C-cell tumors4. Foundayo is not available over the counter and has no US type 2 diabetes indication, though the ACHIEVE trials studied that condition. Foundayo's approved role is long-term weight management under a prescriber's care.

Where can I learn about peptides?

Orforglipron has moved from code name to approved tablet, and the coverage has tracked each step. To help you separate published results from commentary, every article in Superpower’s peptide library is written and fact-checked by a team of health journalists and licensed clinicians.

Read how GLP-1, the gut hormone whose receptor orforglipron activates, fits into the broader science behind peptides.

Important safety information

Orforglipron is approved by the FDA as Foundayo (April 1, 2026) for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, and is not approved for type 2 diabetes in the US. Orforglipron is not a compounded product; Foundayo is the FDA-approved form. Orforglipron is not prescribed, compounded, or dispensed through Superpower. This page is provided for educational purposes only and does not constitute medical advice.

Foundayo carries a boxed warning for the risk of thyroid C-cell tumors and is contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Populations of particular theoretical concern based on the GLP-1 receptor agonist class profile and trial exclusion criteria include: personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); history of pancreatitis; severe gastroparesis or other significant gastrointestinal motility disorders; pregnancy, planning pregnancy, or breastfeeding (safety in pregnancy has not been established); type 1 diabetes (not studied); under 18 years of age (pediatric safety not established); severe renal or hepatic impairment (not studied); known hypersensitivity to orforglipron or any formulation component.

Warnings (class-level GLP-1 receptor agonist considerations, extrapolated from approved GLP-1 agonist labeling): rodent thyroid C-cell tumors at clinically relevant exposures with GLP-1 receptor agonists that are active in rats and mice (orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents; the human relevance of these rodent tumors has not been determined); class-associated signals for acute pancreatitis, acute gallbladder disease, and hypoglycemia (particularly when used with insulin or sulfonylureas); gastroparesis exacerbation; possible dehydration-induced acute kidney injury secondary to severe GI symptoms; potential delayed gastric emptying with implications for perioperative aspiration risk. Orforglipron-specific warnings appear in the FDA-approved Foundayo labeling.

Common side effects reported in Phase 2 and Phase 3 clinical trials: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, and eructation. These were predominantly mild to moderate in severity and most frequent during dose escalation phases. Treatment discontinuation due to adverse events ranged from approximately 4% to 10% across Phase 3 trials and dose levels; in a Phase 2 obesity trial, digestive side effects led 10% to 17% of participants to stop treatment.

Long-term data limitations: In ACHIEVE-4, orforglipron showed cardiovascular safety compared with insulin glargine in adults with type 2 diabetes at increased cardiovascular risk, with major cardiovascular events in 4.2% vs 5.0%17; this result does not show cardiovascular benefit, and cardiovascular outcomes in people with obesity without diabetes have not been reported. Long-term thyroid safety, pancreatitis incidence beyond trial durations, and effects in special populations (renal and hepatic impairment, pregnancy, and pediatrics) have not been fully characterized in completed trials. The long-term durability of weight loss and the extent of weight regain after discontinuation have not been established in peer-reviewed publications as of November 2026.

Compound reference: PubChem CID 13731970623. The FDA-approved Foundayo prescribing information24 is the authoritative label.

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to orforglipron (Foundayo). Orforglipron is an FDA-approved prescription medication available only through licensed prescribers for its approved indication. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

More peptide science